ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Hemofagocytaire lymfohistiocytose (HLH) Richtlijnen en literatuur

Richtlijnen

Er is op dit moment geen richtlijn voor HLH.

Literatuur 

  1. Emile JF et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127(22): 2672-2681. doi: 10.1182/blood-2016-01-690636
  2. Henter JI et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Medical and pediatric oncology 1997; 28(5): 342-347.
  3. Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood 2015; 125(19): 2908-2914. doi: 10.1182/blood-2015-01-551622
  4. Brisse E, et al. Understanding the spectrum of haemophagocytic lymphohistiocytosis: update on diagnostic challenges and therapeutic options. British journal of haematology 2016; 174(2): 175-187. doi: 10.1111/bjh.14144
  5. Brisse E et al. Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities. British journal of haematology 2016; 174(2): 203-217. doi: 10.1111/bjh.14147
  6. Schram AM et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. British journal of haematology 2016; 172(3): 412-419. doi: 10.1111/bjh.13837
  7. Otrock ZK et al. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. American journal of hematology 2014. e-pub ahead of print 2014/12/04; doi: 10.1002/ajh.23911
  8. Schram AM et al. Marked hyperferritinemia does not predict for HLH in the adult population. Blood 2015; 125(10): 1548-1552. doi: 10.1182/blood-2014-10-602607
  9. Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annual review of medicine 2015; 66: 145-159. doi: 10.1146/annurev-med-061813-012806
  10. Chellapandian D et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol 2013; 162(3): 376-382. e-pub ahead of print 2013/05/23; doi: 10.1111/bjh.12386
  11. Das R et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood 2016; 127(13): 1666-1675. doi: 10.1182/blood-2015-12-684399
  12. Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH); update 2010. Journal of pediatric hematology/oncology 2011; 33(1): 35-39. e-pub ahead of print 2010/11/23; doi: 10.1097/MPH.0b013e3181f84a52
  13. Jordan MB, Filipovich AH. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of a thousand miles begins with a single (big) step. Bone marrow transplantation 2008; 42(7): 433-437. doi: 10.1038/bmt.2008.232
  14. La Rosee P. Treatment of hemophagocytic lymphohistiocytosis in adults. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2015; 2015(1): 190-196. doi: 10.1182/asheducation-2015.1.190
  15. La Rosee P. Alleviating the storm: ruxolitinib in HLH. Blood 2016; 127(13): 1626-1627. doi: 10.1182/blood-2016-02-697151
  16. Maschalidi S et al. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood 2016; 128(1): 60-71. doi: 10.1182/blood-2016-02-700013
  17. Seo JJ. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: recent advances and controversies. Blood research 2015; 50(3): 131-139. doi: 10.5045/br.2015.50.3.131

 

Ga terug naar de HLH homepage of lees meer over HLH:

Ga terug naar de algemene homepage Behandelprotocollen.